Common Limb Length in One-anastomosis Gastric Bypass
Common Limb Length in One-anastomosis Gastric Bypass
Evaluation of the effect of the common limb length on the outcome of laparoscopic single
 anastomosis gastric bypass in morbidly obese patients.

 Two groups of patients: one group with a common limb length of about 200 cm distal to the
 ligament of Treitz and the second group with a common limb length of 300 cm proximal to the
 ileocecal valve.

 Groups are evaluated regarding percentage of excess weight loss, resolution of comorbidities,
 and long term complications.
The present study is a prospective, randomized comparative clinical trial involving 60
 patients (due to limited flow rate and high expenses [14]) who will be subjected to
 laparoscopic single anastomosis gastric bypass at the department of surgery, Mansoura
 university, Mansoura, Egypt at the period from May 2016 to May 2019.

 Patients will be randomly allocated into 2 groups with 30 patients undergoing LSAGB with
 measuring two meters from the duodenojejunal junction, and the other 30 undergoing LSAGB with
 measuring three meters from the ileocecal valve.

 Informed consent will be obtained from all patients participating in the study after
 explaining the patients about the benefits and the potential risks involved.

 Inclusion criteria:

 1. Morbid obesity with BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 associated with one or more
 co-morbidities (type 2 diabetes, arterial hypertension, sleep apnea, dyslipidemia,
 arthritis).

 2. Age between 18 and 60 years old.

 Exclusion criteria:

 1. Pregnancy or desire to be pregnant during the study.

 2. Abnormal findings on upper GI endoscopy.

 3. Presence of chronic diarrhea (≥ 3 liquid or loose stools per day, over a period of more
 than 4 weeks).

 4. Obesity due to organic disease e.g, cushing disease and hypothyroidism.

 5. Previous bariatric surgery.

 6. Coexisting severe hepatic, pulmonary, renal, cardiovascular, neurological and
 psychiatric diseases.

 Subjects and preoperative evaluation:

 Preoperative evaluation including

 -  Clinical history.

 -  Thorough Physical examination.

 -  BMI is calculated as weight in kilogram divided by height in metre2.

 -  Routine laboratory tests and urinalysis. Throid function and serum cortisol done to rule
 out organic illness.

 -  Fasting blood sugar, HbA1c and lipid profile.

 -  ABG and pulmonary function routinely done for all patients preoperative.

 -  Fecal fat excretions done to follow up incidence of steatorrhea.

 -  Imaging studies (chest radiograph and ultrasound abdomen).

 -  Routine upper GI endoscopy will be done preoperative.

 Outcomes:

 The primary outcome measures excess weight loss % one and 2 years after surgery.

 Secondary outcomes measures:

 -  Weight loss according to the absolute weight loss (time frame: 1, 3, 6, 12, 18 and 24
 months after surgery).

 -  Waist size reduction according to the absolute waist size (time frame: 1, 3, 6, 12, 18
 and 24 months after surgery).

 -  Medical and surgical complication (anastomotic leaks, biliary reflux, bowel obstruction,
 anastomotic ulcers, anastomotic stenosis, chronic gastritis, esophagitis, iron
 deficiency anemia) followed at 1, 12 and 24 months after surgery.

 Early complications are detected during the 1st month following surgery while late
 complications defined from 1 to 24 months after surgery.

 -  Improvement in glycemic parameters (HbA1C, Fasting blood sugar, Post lunch blood sugar).

 -  Remission of hypertension and lipid profile changes.

 -  Patient's quality of life 6, 12, 24 months after surgery (according to the Bariatric
 Analysis and Reporting Outcome System questionnaire "BAROS").

 -  Frequency of diarrhea based on the gastrointestinal quality of life index (GIQLI)
 questionnaire.

 -  Rate of revision due to intolerable complications, or due to insufficient weight loss.

 The outcomes will be planned to be monitored and analyzed at 3 months interval for 24 months.

 Prevention of surgical site infection and perioperative antiplatelet drug administration will
 be managed according to validated criteria [15, 16].

 Surgical technique:

 Patients are placed in the reverse Trendelenburg position with legs spread. The surgeon
 stands between patient's legs. The monitor is at the head of the operating-table to the left
 side of the patient. We always use a 30_ optic and five trocars.

 The technique used for LSAGB has been described [16]. A 14-16 cm long gastric tube is created
 using a 60 mm stapler starting on the lesser curvature at the crow's foot level. It is
 tailored following the edge of a 38F calibrating orogastric tube up to the angle of His. A
 loop gastroenterostomy is then created with the small bowel about 200 cm distal to the
 ligament of Treitz with the same stapler using a 60 mm blue cartridge for the first group and
 about 300cm proximal to the ileocecal valve for the second group. The gastrojejunal
 anastomosis is then closed with a double-layer locking running 2-0 suture. All patients are
 checked by an intraoperative methylene blue test at the end of the procedure. A drain tube is
 placed in all the patients.

 Postoperative care:

 All the patients are monitored in the recovery room and transferred to the wards or to the
 intensive care unit when needed. Early postoperative ambulation is strongly encouraged with
 patients getting out of bed the evening of the surgery and walking by postoperative day 1. A
 clear liquid diet started on day 2, and advanced to pureed food 1 week later, and to solid
 food by the fourth postoperative week. At discharge the drain is removed and detailed dietary
 instructions provided to the patients. Patients are advised to take daily multivitamins and
 supplemental minerals, as well as proton pomp inhibitor (PPI) prophylaxis for 6 months.
 Follow-up scheduled at 1, 3, 6, 12, and 24 months postoperatively, then twice a year.

 Statistical analysis will be performed using the SPSS 19 system (SPSS Inc., Chicago, IL,
 United States). Continuous data will be expressed as the mean ± SD, and categorical variables
 expressed as the percent changes. Statistical significance defined as P values < 0.05.
Inclusion Criteria:

 1. Morbid obesity with BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 associated with one or more
 co-morbidities (type 2 diabetes, arterial hypertension, sleep apnea, dyslipidemia,
 arthritis).

 2. Age between 18 and 60 years old.

 Exclusion Criteria:

 1. Pregnancy or desire to be pregnant during the study.

 2. Abnormal findings on upper GI endoscopy.

 3. Presence of chronic diarrhea (≥ 3 liquid or loose stools per day, over a period of
 more than 4 weeks).

 4. Obesity due to organic disease e.g, cushing disease and hypothyroidism.

 5. Previous bariatric surgery.

 6. Coexisting severe hepatic, pulmonary, renal, cardiovascular, neurological and
 psychiatric diseases.